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Abstract 
The red blood cell distribution width (RDW) is an index of the heterogeneity of 
circulating red blood cell size which along with other standard complete blood count (CBC) 
parameters is used to identify hematological system diseases. Besides hematological 
disorders, several clinical studies have shown that an increased in the RDW may be 
associated with other diseases including acute pancreatitis, chronic kidney disease, 
gastrointestinal disorders, cancer, and of special interest in this review, cardiovascular 
disease (CVD). The diagnostic and prognostic value of RDW in different CVD (acute 
coronary syndrome, ischemic cerebrovascular disease, peripheral artery disease, atrial 
fibrillation, heart failure, and acute ischemic stroke) has been reviewed in this article, to 
provide an understanding how its measurement may be applied to improve the management 
of these conditions. 
Keywords: RDW, Biomarker, Cardiovascular diseases 
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Introduction 
Cardiovascular disease (CVD) remains an important cause of mortality, and has a 
huge burden on health (1) especially in developing countries. Lifestyle and age are two key 
factors in the development of CVD (2). The incidence of CVDs is increasing worldwide and 
comprises several specific conditions, that include: ischemic heart disease (IHD), 
cerebrovascular disease, hypertensive heart disease, peripheral vascular disease, heart 
failure (HF) and atrial fibrillation (AF) (3). Ischemic heart disease and stroke are currently 
responsible for most cases of CVD (4). There are multiple risk factors associated with CVD 
(4), which can be divided into classical risk factors, that have been known for decades 
(including smoking, diabetes mellitus, hypertension, abnormal lipids and obesity) and novel 
risk factors (such as C-reactive protein (CRP), cystatin C, homocysteine, adipokines, 
adiponectin, resistin, osteoprotegerin, genetic factors, and red blood cell distribution width 
(RDW) (1). Most people at risk have several risk factors and multiple risk factors combination 
may have a synergistic impact to increase risk of CVD (4, 5). 
The RDW is a simple, rapid and easily available assessment measure of RBC size 
heterogeneity, which can be calculated from the standard deviation (SD) of erythrocyte 
volumes for the mean corpuscular volume (MCV) (6). The reference range variation is due to 
difference in the instruments used to measure the RDW (7). However the common minimum 
and maximum of RDW physiological range are 11% and 15%, respectively (6).  
RDW is a routinely reported as a part of complete blood count. Recently, researches 
has demonstrated possible relations between RDW and many other clinical conditions other 
than anemia. Different clinical conditions alter RDW in various ways which are mostly 
provoked by inflammation, nutritional disturbances and alteration in erythropoiesis. Such 
alteration usually effect bone marrow and erythropoietin hormone. This hormone regulate 
production, maturation and survival of erythrocytes. Abnormal increase in erythropoietin 
production will result in increase in RDW (8). Inflammation will inhibit erythropoietin and RBC 
production as well as reducing the survival rate of RBCs by damaging RBC memberane and 
increasing fragility because of increased oxidative stress (9). Moreover, deficiencies of iron 
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(10), vitamin B12 (11), and folate (12) are considered as the main factors which are directly 
related to the nutritional status. Other clinical conditions which can increase RDW are 
hemolytic anemia and sickle cell anemia are hematological diseases (7). Moreover, elevated 
RDW is also observed in non-hematological diseases which mostly interfere with red blood 
cell production because of alteration in overall inflammatory status. Such changes are seen 
with inflammatory bowel disease (13), systemic lupus erythematosus (14), hepatobiliary 
disease (15)  and Behçet’s disease (7, 16).  
There are several studies showing that an increased RDW is related to CVD 
complications (17, 18).  RDW at the upper limit of normal range is associated with a 
significantly increased risk of CVD and its mortality (19). The exact mechanism behind the 
relation of RDW values and developing different pathologies are not clearly understood. 
Anisocytosis can directly affect many clinical conditions including heart failure. High 
anisocytosis RBCs usually indicated the decreased oxygen capacity. Moreover, abnormal 
RBCs may participate in development of cardiac fibrosis by amplification of inflammation 
(20). Such effects will end up in decreased oxygenation many organs including 
cardiomyocytes and predispose human cardiovascular system to different pathologies 
including ischemia and organ failure (21). The purpose of this review was to summarize the 
results of recent studies that have investigated the diagnostic and prognostic value of RDW 
in CVD. 
 
RDW as a biomarker in coronary artery disease (CAD)  
There are several studies investigating the association of increased RDW level with 
CVD complications. For instance, Lippi et al. assessed 456 acute coronary syndrome (ACS) 
and 1848 non-ACS patients and reported that median RDW level was significantly higher in 
ACS patient compared to non-ACS control group. Furthermore, it was shown that the 
sensitivity of ACS diagnosis could be improved by measuring cardiac troponin T and RDW 
simultaneously (22). Uyarel et al. investigated the association between the RDW on 
admission with incidence of in-hospital mortality rate in 2506 patients with ST elevation 
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myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). 
The authors showed that compared with patients with a normal RDW on admission, patients 
with increased RDW had higher in-hospital mortality rate (23). Interestingly, investigation on 
370 patients with STEMI and 156 normal coronary angiographic subjects showed that, in 
young patients, an increased RDW was associated with STEMI while this association was 
not observed in elderly patients (24). Furthermore, the RDW was correlated with the number 
of stenotic coronary artery as well as fragmented QRS in patients with non ST evaluation 
myocardial infraction (NSTEMI) or unstable angina (UA) (25). Similarly, it has been reported 
that a high RDW at the time of hospital admission in patients with stable coronary artery 
disease (SCAD) is associated with an enhanced mortality and incidence of ACS within the 
subsequent year (26). RDW may also be helpful in evaluation of risk of mortality after ACS 
(27). Nabais et al. studied 1796 patients with ACS, and showed that increased RDW is an 
independent risk factor for 6-month mortality or MI in patients with ACS (28). Poludasu et al. 
studied patients who underwent PCI and showed that an increased RDW was a risk factor 
for mortality in patients with normal level of hemoglobin at baseline (29). An evaluation of 
560 patients with diabetes mellitus and SCAD who underwent PCI showed that there was a 
significant association between RDW and long-term mortality in these patients (30). 
Skjelbakken et al. reported a positive association between RDW and risk of MI in the general 
population. The risk of MI was increased by approximately 13% for every 1% increment in 
RDW (31). Gul et al. studied 310 patients with UA or NSTEMI and found that the RDW at 
time of hospital admission was a significant predictor of worse outcomes in these patients 
and mortality in the next three years was significantly higher in the patients with high RDW 
level (32). Isik et al. followed up 193 patients who underwent coronary angiography and 
found that there was a higher RDW in patients who underwent angiography compared with 
those subjects with normal coronary arteries CAD (33). Dabbah et al. studied 1709 patients 
with acute MI and results showed that RDW on admission and RDW elevation during the 
period of hospitalization were associated with poor clinical outcomes and mortality in 
patients with MI with and without anemia (34). Vaya et al. studied the association between 
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CVD events recurrence with RDW level in MI patients and found that high level of RDW 
increased the risk of CVD events by 6 fold. (35). It has been consistently demonstrated that 
there is an association between high RDW level at the time of hospital admission with high 
sensitivity C-reactive protein (hsCRP), N-terminal pro-brain natriuretic peptide (NT pro-BNP), 
presence of more severe coronary arteries lesions and intracoronary thrombotic burden in 
patients with STEMI who underwent primary PCI (36). In another study, 251 patients who 
had a bare-metal stent implantation, and who underwent control coronary angiography were 
investigated by Kurtul et al. to evaluate relationship between in-stent restenosis and level of 
RDW. They report that RDW level could predict in-stent restenosis before control coronary 
angiography (37).  
 
Prognostic role of RDW in ischemic cerebrovascular disease  
There are several studies investigating the association between RDW and stroke. 
Söderholm et al. measured RDW in 26879 participants from the general population, without 
a history of previous stroke or CAD event, and found that subjects who had RDW level in the 
highest quartile had an increased subsequent incidence of stroke and cerebral infarction. 
However no significant relationship was found between RDW and cerebral hemorrhage  
(38). Furthermore, it has been shown that there is a positive correlation between both hs-
CRP and RDW with carotid intimal-medial thickness in patients suffering from primary 
ischemic stroke. This study also suggested RDW may be a predictor of the presence carotid 
artery atherosclerosis (39). Vayá et al. evaluated the correlation between RDW and stroke in 
163 patients hospitalized due to cryptogenic stroke and 186 healthy subjects who were 
adjusted according to age, sex, anemia, lipid profile and other potential confounders. They 
found that a high RDW was associated with the increase risk of cryptogenic stroke (40). 
Moreover, in a study on 847 patients with a first-ever episode of acute cerebral infarction it 
was found that high value of RDW was correlated with adverse functional outcome (41). 
Ramírez-Moreno et al. measured the RDW in 224 patients with first-ever ischemic stroke 
and 224 cases without cerebrovascular disease and found a stepwise association between 
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RDW levels and risk of cerebral infarction (42). A higher RDW was also observed in 88 
stroke patients with a poor Glasgow Coma Scale (GCS), National Institutes of Health Stroke 
Scale (NIHSS) as well as Canadian Neurological Scale (CNS). This study showed that the 
RDW may be a biomarker for the prediction of severity and functional outcomes in stroke 
patients (43). Siegler et al. undertook a retrospectively investigated of RDW in 179 patients 
with aneurysmal subarachnoid hemorrhage (aSAH) admitted to a neurointensive care unit 
and found that there is a significant association between elevated RDW level and incidence 
of cerebral infarction and adverse clinical outcomes after aSAH (44). Kaya et al. showed that 
in i53 patients with HF who had had a stroke there was a significantly increased baseline 
RDW in comparison with patients without stroke, suggesting that RDW may be a predictive 
marker for the incidence of stroke in HF patients. A RDW >15.2% at the time of admission 
had 87% sensitivity and 74% specificity for stroke incidence in HF patients (45). Taken 
together, these results support the proposition that RDW could be a useful biomarker for 
stroke with a reasonablel predictive value in these patients. 
 
Role of RDW in peripheral artery disease (PAD) and RDW 
There is compelling evidence showing that RDW may be a biomarker of PAD. It has 
been consistently reported that a high RDW is associated with an increased risk of death in 
patients suffering from PAD. In these patients, the risk of mortality increased almost 10% for 
every one percent increment in RDW (46). Zalawadiya et al. measured RDW in 6950 
participants from general population and after adjustment for potential confounders they 
showed that, there is a direct relationship between RDW and prevalence of PAD (47). 
Demirtas et al. studied 82 PAD patients and showed that RDW increased incrementally with 
the progression of PAD severity stages (48). 
 
RDW a novel biomarker for atrial fibrillation (AF)   
Several studies have evaluated the association between RDW and AF. Ertas et al. 
studied 132 patients undergoing coronary artery by-pass graft (CABG) and measured AF 
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before and after surgery in these patients. Pre-operative RDW was significantly lower in 
patients who developed post-operative AF. However no association was observed between 
the post-operative RDW value and post-operative AF. Further studies showed that the 
sensitivity and specificity for prediction of post-operative AF at the level of RDW >13.4% 
were 61% and 60%, respectively (49). Korantzopoulos et al. have reported that the 
sensitivity and specificity to predict incidence of AF at the pre-operative level of RDW 
>13.3% were 80% and 60%, respectively in patients undergoing cardiac surgery (50). 
Similarly, it has been demonstrated that the RDW was significantly higher in patients with 
paroxysmal non-valvular AF compared with patients without this. They also reported that 
RDW of >12.5% had 48% sensitivity and 67% specificity for the incidence of paroxysmal AF 
(51). Güngör et al. showed patients with AF had a higher RDW compared to the control 
group, suggesting that increased RDW may be a risk marker for non-valvular AF (52). 
Adamsson Eryd et al. followed up 27124 participants without a prior history of AF for 
approximately 13 years, and reported that there was a positive association between RDW 
and risk of AF in the study group (53). Moreover, RDW  was shown to be associated with 
recurrence of late AF after monitoring 299 patients with AF for a mean of two years(54). To 
further investigate whether elevated RDW is associated with the mortality rate in AF patients, 
Wan et al. followed up AF patients for a mean of 3 years and found that increased RDW 
level was associated with an enhanced mortality rate, and with major adverse events in 
these patients (55). Kaya et al. studied 619 patients with non-valvular AF and showed that 
increased level of RDW was associated with both left atrial stasis and thromboembolic 
events in patients with non-valvular AF (56). These results clearly suggest that RDW could 
be a valid biomarker for both prognosis and diagnosis in AF patients. 
 
Prognostic and diagnostic value of RDW in Heart failure 
In recent years growing evidence suggest that RDW is a key player in increasing risk 
of incidence and poor prognosis of heart failure (HF). Emans et al. studied 17533 subjects 
for a mean period of 11 years and found a non-linear association between RDW level and 
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risk of HF even after adjusting for other risk factors including C-reactive protein, ferritin and 
iron. They also reported that there was an inverse association between RDW level and 
physical inactivity, however this association was not correlated with HF (57). Borné et al. 
studied 26784 healthy subjects with no prior history of stroke, MI, or HF, and followed up 
them for a mean of 15 years to investigate the association between RDW and long-term 
incidence of hospitalization for HF. Patients with a high RDW had significantly higher risk of 
HF incidence, but after adjustment for other risk factors including hs-CRP, N-terminal pro-B-
type natriuretic peptide and cystatin C, the significance of the association between RDW and 
HF incidence was reduced substantially (58). Furthermore, an elevated RDW was shown to 
be correlated with the increased left ventricular filling pressure in patients with acute HF (59). 
To further support the clinical significance of RDW in HF patients, Nishizaki et al. evaluated 
160 patients who died as a result of HF and found that RDW >16.5% was significantly 
associated with fatal HF (60). Uemura et al. measured RDW at the time of hospital 
admission and during hospitalization in patients with acute decompensated HF and reported 
that the alteration in RDW level during hospital stay, can predict adverse outcomes and all-
cause death among patients (61). The results of a meta-analysis of 18288 HF patients 
showed that level of RDW on admission and discharge, as well as its variation during 
treatment, can be used as marker to predict prognosis of HF. This meta-analysis also 
revealed that HF patients with higher RDW had poorer prognosis (62). The RDW can be 
high in patients who have both HF and diabetes mellitus (DM). Xanthopoulos et al. studied 
218 patients with both HF and DM and measured RDW at hospital admission, discharge and 
after 4, 8, 12 months of discharge. There was an association between RDW on admission 
and higher incidence of clinical events in diabetic or non-diabetic HF. However, it was shown 
that RDW one year after discharge was significantly higher in HF patients with DM compared 
to non-diabetic HF patients (63). It has been demonstrated that increased RDW after 4 days 
of hospitalization, increased risk of 30-day mortality up to 4-fold in patients with acute 
decompensated HF, suggesting that these patients with elevated RDW require more care in 
the first days of hospitalization (64). 
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Hypertensive heart disease and RDW 
Several studies suggested that RDW level is increased in hypertensive patients. 
Tanindi et al. showed that RDW is increased in pre-hypertensive and hypertensive patients 
compared with healthy subjects independent of other factors such as age and inflammatory 
status. Moreover, it has been demonstrated that elevated RDW is strongly associated with 
systolic and diastolic blood pressures (18). Bilal et al. evaluated 100 hypertensive patients 
and found that most of these patients had an increased levels of RDW (65). Similarly, Ozcan 
et al. validated the association between RDW and hypertension in 247 patients with 
essential hypertension and found that RDW is significantly higher in patients with non-dipper 
hypertension compared with the dipper hypertensive patients (66). Furthermore, it has been 
demonstrated that nebivolol, an anti-hypertensive drug, decreased RDW in new essential 
hypertensive patients, supporting the hypothesis that RDW could be used in clinic as a novel 
biomarker for evaluating the hypertension-associated complications in cardiovascular 
disease (67). 
 
Conclusion 
Several studies have investigated the relationship of RDW with CVD. RDW either 
alone or in combination with other cardiac biomarkers may improve diagnosis and assessing 
prognosis of CVD including ACS, ischemic cerebrovascular disease, peripheral artery 
disease, atrial fibrillation, heart failure, and acute ischemic stroke. In brief, elevated RDW 
has unfavorable effects on CVD and is associated with increased risk of incidence, adverse 
outcome and mortality of CVD. The effects of increased RDW on different type of CVD are 
showed in Figure 1. 
The exact relevant mechanisms are unclear and not yet fully understood (Figure 2). 
Although RDW may be a biomarker that is rapid and easily available assessment in almost 
all health facilities and obtained as a part of complete blood count, for evaluating the severity 
and prognosis of patients with CVDs, further investigations are needed to assess the 
efficacy as well as accuracy of RDW in CVDs. 
11 
 
References 
1. Payne RA. Cardiovascular risk. British Journal of Clinical Pharmacology. 
2012;74(3):396. 
2. Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. 
The American journal of cardiology. 2010;105(1 Suppl):3A. 
3. Bowry A, Lewey J, Dugani S, Choudhry N. The Burden of Cardiovascular Disease in 
Low-and Middle-Income Countries: Epidemiology and Management. The Canadian journal 
of cardiology. 2015;31(9):1151. 
4. Norhammar A, Schenck-Gustafsson K. Type 2 diabetes and cardiovascular disease 
in women. Diabetologia. 2013;56(1):1. 
5. Tran D, Zimmerman L. Cardiovascular risk factors in young adults: a literature 
review. The Journal of cardiovascular nursing. 2015;30(4):298. 
6. Danese E, Lippi G, Montagnana M. Red blood cell distribution width and 
cardiovascular diseases. Journal of thoracic disease. 2015;7(10):E402. 
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Table and Figure legends 
Table 1. RDW: red blood cell distribution width; CAD: coronary artery disease; IHD: ischemic 
heart disease; ICD: Ischemic cerebrovascular disease; HF: heart failure; MI: myocardial 
infarction; PCI: percutaneous coronary intervention; ACS: acute coronary syndrome; 
NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; 
UA: unstable angina; stable coronary artery disease; aSAH: aneurysmal subarachnoid 
hemorrhage; OSAHS: obstructive sleep apnea hypopnea syndrome; PAD: Peripheral Artery 
Disease; CABG: coronary artery by-pass graft; AF: atrial fibrillation; hs-CRP: high sensitivity 
C-reactive protein; DM: diabetes mellitus; ADHF: acutely decompensated HF; HHD: 
Hypertensive heart disease. 
Figure 1. The effects of increased RDW level on different types of CVD, supporting the 
clinical significance of this molecule in cardiovascular diseases. 
Figure 2. Association between increased RDW and CVD. 
 
 
